Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Sees Significant Drop in Short Interest
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Sees Significant Drop in Short Interest
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 31,000 shares, a decline of 11.9% from the July 15th total of 35,200 shares. Based on an average daily trading volume, of 9,800 shares, the short-interest ratio is presently 3.2 days.
智能製藥國際公司(場外交易代碼：IPCIF-GET評級)(東京證券交易所代碼：I)7月份空頭股數股價大幅下跌。截至7月31日，空頭股數共有3.1萬股，較7月15日的3.52萬股下降11.9%。以日均成交量9,800股計算，目前短息比率為3.2天。
Intellipharmaceutics International Price Performance
IntelliPharmPharmtics International價格表現
OTCMKTS IPCIF traded down $0.02 on Monday, hitting $0.09. 1,000 shares of the company were exchanged, compared to its average volume of 10,463. The firm has a market capitalization of $2.81 million, a P/E ratio of -0.31 and a beta of 1.67. The company's 50 day moving average price is $0.10 and its 200-day moving average price is $0.12. Intellipharmaceutics International has a twelve month low of $0.08 and a twelve month high of $0.30.
OTCMKTS IPCIF週一下跌0.02美元，觸及0.09美元。該公司的股票成交量為1000股，而其平均成交量為10,463股。該公司的市值為281萬美元，市盈率為-0.31，貝塔係數為1.67。該公司的50日移動均線價格為0.10美元，其200日移動均線價格為0.12美元。IntelliPharmPharmtics International的12個月低點為0.08美元，12個月高位為0.30美元。
Intellipharmaceutics International (OTCMKTS:IPCIF – Get Rating) (TSE:I) last released its quarterly earnings results on Thursday, July 21st. The company reported ($0.05) EPS for the quarter.
IntelliPharmPharmtics International(OTCMKTS：IPCIF-GET Rating)(東京證券交易所代碼：I)最近一次發佈季度收益報告是在7月21日星期四。該公司公佈了該季度每股收益(0.05美元)。
Intellipharmaceutics International Company Profile
智能製藥國際公司簡介
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
IntelliPharmPharmtics International Inc.是一家制藥公司，在美國研究、開發和製造新型和仿製藥的控釋和靶向釋放口服固體劑量藥物。該公司在神經學、心血管、胃腸道、糖尿病和疼痛等不同治療領域基於其獲得專利的HyperMatrix技術開發各種藥物輸送系統、候選產品和一系列產品。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Intellipharmaceutics International (IPCIF)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc
- 免費獲取StockNews.com關於IntelliPharmPharmtics International(IPCIF)的研究報告
- 第二季度財報季最熱門的五個電話
- 以下是一個簡單的4只股票投資組合，它可以跑贏大盤
- AMC娛樂公司是在對猩猩採取快速行動嗎？
- 以下是《降低通脹法案》如何提振電力庫存
- 機構調整高收益Foot Locker，Inc.的控股
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.
獲得IntelliPharmPharmtics International Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對IntelliPharmPharmtics International和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。